|
KMID : 1141520230380010025
|
|
Endocrinology and Metabolism
2023 Volume.38 No. 1 p.25 ~ p.33
|
|
|
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
|
|
Adie Viljoen
Stephen C. Bain
|
|
|
Abstract
|
|
|
|
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease.
|
|
|
KEYWORD
|
|
|
Glucagon-like peptide 1, Diabetes mellitus, type 2, Renal insufficiency, chronic
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|